Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 30, 2008 Brian Orelli	Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest.
The Motley Fool May 7, 2008 Brian Orelli	Teva's on a Tear The generic-drug maker can't be stopped.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool November 3, 2009 Brian Orelli	Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool May 5, 2009 Brian Orelli	Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool February 13, 2008 Brian Orelli	Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted.
The Motley Fool April 13, 2010 Brian Orelli	Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development.
The Motley Fool October 22, 2008 Brian Orelli	Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places.
The Motley Fool June 11, 2008 Brian Orelli	Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note.
The Motley Fool October 30, 2008 Brian Orelli	Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool April 11, 2008 Brian Orelli	Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool October 31, 2007 Brian Orelli	From Apples to Apple Pie at Teva Year-over-year sales skyrocket at Teva Pharmaceutical, due to the launch of more than 25 new products. Investors, take note.
The Motley Fool April 12, 2011 Brian Orelli	How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool October 21, 2008 Brian Orelli	Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool March 5, 2008 Brian Orelli	Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent.
The Motley Fool September 15, 2008 Brian Orelli	Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal.
The Motley Fool February 28, 2006 Stephen D. Simpson	Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
The Motley Fool September 25, 2008 Brian Orelli	Teva Heads to Japan It's conquering the world, slowly but surely. But is it still a value play?
The Motley Fool April 30, 2009 Brian Orelli	A Great Generic Recovery After getting punished for taking on an acquisition, Mylan is doing pretty well.
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
The Motley Fool April 7, 2010 Brian Orelli	Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious.
The Motley Fool September 29, 2010 Brian Orelli	A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals.
The Motley Fool October 27, 2010 Brian Orelli	Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan.
The Motley Fool December 9, 2010 Brian Orelli	Here Comes Another Oral MS Drug Good for Teva, bad for the rest.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool October 29, 2007 Brian Orelli	The Extended Release That Wasn't The FDA is investigating Teva's generic version of Wellbutrin XL. Investors, take note.
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool October 29, 2007 Brian Orelli	Foolish Forecast: Tenacious Teva The generic drug maker releases earnings shortly. Here's a look at whether investors should expect a generic quarter or a blockbuster.
The Motley Fool November 8, 2005 Stephen D. Simpson	Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares?
The Motley Fool February 11, 2010 Brian Orelli	Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years.
The Motley Fool November 26, 2010 Anders Bylund	Teva Is Running Scared A personal take on the MS medicine market: A little bit of marketing spin keeps the doctor away, but too much makes you a jerk.
The Motley Fool May 15, 2008 Brian Orelli	Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.